> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-200/
- Published: 2018-10-21T12:00:00.000Z
- Updated: 2026-09-15T00:39:31.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142641

[**Quantitative Efficacy/Risk Info in DTC Ads**](https://www.fdaweb.com/quantitative-efficacy-risk-info-in-dtc-ads/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements.” 10/19/2018

[**Regulatory Review Period for SK Chemicals’ Afstyla**](https://www.fdaweb.com/regulatory-review-period-for-sk-chemicals-afstyla/)  
*Federal Register* notice: FDA determines for patent extension-related purposes the regulatory review period for SK Chemicals’ Afstyla. 10/19/2018

[**Regulatory Review Period for Regeneron’s Dupixent**](https://www.fdaweb.com/regulatory-review-period-for-regenerons-dupixent/)  
*Federal Register* notice: FDA determines for patent extension-related purposes the regulatory review period for Regeneron Pharmaceuticals’ Dupixent. 10/19/2018

[**6 Medical Device Classification Orders Posted**](https://www.fdaweb.com/6-medical-device-classification-orders-posted/)  
*Federal Register* notices: FDA makes available six medical device classification orders. 10/19/2018

[**Regulatory Review Period for Genentech’s Ocrevus**](https://www.fdaweb.com/regulatory-review-period-for-genentechs-ocrevus/)  
*Federal Register* notice: FDA determines for patent extension-related purposes the regulatory review period for Genentech’s Ocrevus (ocrelizumab). 10/19/2018

[**Draft Guide on Cybersecurity for Medical Devices**](https://www.fdaweb.com/draft-guide-on-cybersecurity-for-medical-devices/)  
*Federal Register* notice: FDA has made available a draft guidance entitled “Content of Premarket Submissions for Management of Cybersecurity in Medical Devices.” 10/18/2018

[**Study of Accelerated Approval Disclosures**](https://www.fdaweb.com/study-of-accelerated-approval-disclosures/)  
*Federal Register* notice: FDA seeks comments on a new proposed research study entitled “Experimental Study of an Accelerated Approval Disclosure.” 10/18/2018